stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) EBITDA
Xenon Pharmaceuticals Inc.'s EBITDA for fiscal 2025 was −$370.5M, compared with −$276.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$439.2M. Over the past ten years it has ranged from −$370.5M (fiscal 2025) to −$8.3M (fiscal 2015) — the current reading is the lowest in ten years. EBITDA has fallen for 5 consecutive fiscal years. Xenon Pharmaceuticals Inc. ranks 572nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$370.5M | — |
| FY2024 | −$276.7M | — |
| FY2023 | −$212.0M | — |
| FY2022 | −$127.5M | — |
| FY2021 | −$78.1M | — |
| FY2020 | −$30.4M | — |
| FY2019 | −$41.9M | — |
| FY2018 | −$37.2M | — |
| FY2017 | −$31.9M | — |
| FY2016 | −$24.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$122.6M | — |
| Mar 2026 | −$111.7M | — |
| Dec 2025 | −$109.2M | — |
| Sep 2025 | −$95.7M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| IRON Disc Medicine, Inc. compare | −$273.8M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. | −$439.2M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on XENE
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement